In tumors where PD-L1 is reactively induced by IFNγ secreted by ACPs, FASN blockade, which disrupts the maturation of PD-L1 on the surface of cancer cells, can be used to overcome adaptive immune resistance. The gene discussed is IFNG; the disease is cancer.